Form 4: Paolo Pucci Reports Stock Option Grant in Replimune Group, Inc.

Director Paolo Pucci reports acquisition of stock options in Replimune Group, Inc.

Summary

• Paolo Pucci, a director of Replimune Group, Inc., filed a Form 4 on April 3, 2024.
• The report details the acquisition of 32,000 stock options on April 1, 2024, at an exercise price of $7.73.
• These options vest entirely on April 1, 2025, and expire on April 1, 2034.
• Following the transaction, Pucci directly owns 32,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction. The grant of options can be seen as a positive sign of alignment between management and shareholders, but it's a routine event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The grant of stock options aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates